Drug intelligence / Profile preview

CTA-382

Development stage: Preclinical
Lead developer: Certa Therapeutics
Modality: Small Molecules

Overview

CTA-382 is a novel small molecule drug developed by Certa Therapeutics. It acts as an antagonist of GPR68 (G protein-coupled receptor 68), a target implicated in fibrotic and inflammatory pathways. The drug is being investigated primarily for its potential to treat chronic kidney diseases, including diabetic nephropathy, by inhibiting the activity of GPR68 and thereby modulating fibrosis and inflammation in affected tissues. As of the latest updates, CTA-382 remains in preclinical development[1][3][9].

Targets

GPR68 (G protein-coupled receptor 68)

Beyond the preview

Go deeper on CTA-382.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTA-382.

Explore the full profile